Literature DB >> 30513347

Enlarged Areas of Pain and Pressure Hypersensitivityby Spatially Distributed Intramuscular Injections ofLow-Dose Nerve Growth Factor.

Line B Sørensen1, Shellie A Boudreau1, Parisa Gazerani2, Thomas Graven-Nielsen3.   

Abstract

Intramuscular injection of nerve growth factor (NGF) causes muscle hyperalgesia without immediate pain. This double-blinded, randomized study assessed pain and muscle hypersensitivity after a single-site bolus NGF injection (5 µg) compared with 5 spatially distributed, low-dose NGF injections (1 µg, 4 cm distance) into the tibialis anterior (TA) muscles in 20 healthy subjects. Injection pain was rated on a visual analog scale. Reports of muscle pain with functional tasks (Likert scale score) and the presence of spontaneous pain were collected daily by using a diary. Pressure pain threshold (PPT), overall pain intensity (numerical rating scale), and pain areas following the TA contraction were collected at baseline; 3 hours; and 1, 3, 7, 14, and 21 days postinjection. Low immediate visual analog scale scores were associated with both injection protocols. Likert scale scores showed moderate pain intensities but no spontaneous pain, until day 12, for both injection protocols (P < .05). Reduced PPTs at the 5- and 1-µg injection sites were found after 3 hours, lasting until day 7 (P < .05). The 1-µg injection provoked decreased PPTs at day 1 (P = .036) at the proximal injection site and at day 1 (P = .02) and day 3 (P = .01) at the distal injection site. The TA muscle contraction resulted in larger pain areas and higher numerical rating scale scores at day 3 for the distributed injections compared with the single-site injection (P < .001). Perspective: Spatially distributed low-dose NGF injections induced prolonged pain, mechanical muscle hypersensitivity, and enlarged contraction-evoked pain areas. These features mirror some clinical muscle pain conditions in which diffuse pain areas and muscle hypersensitivity are present during the activities of daily living. Low-dose NGF injections may be useful for further studies of prolonged pain conditions.
Copyright © 2018 the American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nerve growth factor; hyperalgesia; injection; muscle contraction; pain measurements

Mesh:

Substances:

Year:  2018        PMID: 30513347     DOI: 10.1016/j.jpain.2018.11.005

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  4 in total

1.  Chronic non-inflammatory muscle pain: central and peripheral mediators.

Authors:  Joseph Lesnak; Kathleen A Sluka
Journal:  Curr Opin Physiol       Date:  2019-06-18

2.  Involvement of Oxidative Stress and Nerve Growth Factor in Behavioral and Biochemical Deficits of Experimentally Induced Musculoskeletal Pain in Mice: Ameliorative Effects of Heraclin.

Authors:  Anudeep Kaur; Lovedeep Singh; Saweta Garg; Harmanpreet Kaur; Nirmal Singh; Rajbir Bhatti
Journal:  J Mol Neurosci       Date:  2020-07-16       Impact factor: 3.444

3.  The Effect of Granisetron on Sensory Detection and Pain Thresholds in Facial Skin of Healthy Young Males.

Authors:  Malin Ernberg; Anna Wieslander Fältmars; Milad Hajizadeh Kopayeh; Sofia Arzt Wallén; Therese Cankalp; Nikolaos Christidis
Journal:  Front Neurol       Date:  2020-04-09       Impact factor: 4.003

Review 4.  Nerve Growth Factor Signaling and Its Contribution to Pain.

Authors:  Philip A Barker; Patrick Mantyh; Lars Arendt-Nielsen; Lars Viktrup; Leslie Tive
Journal:  J Pain Res       Date:  2020-05-26       Impact factor: 3.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.